Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma

11 Sept 2007

Abstract excerpt

The combination of fluorescence in situ hybridization with cytoplasmic light chain detection identified chromosome 1p21 deletion in 18 (20%) of 87 patients with multiple myeloma. 1p21 deletion was associated with higher serum calcium level, 13q deletion, and t(4;14). Patients with 1p21 deletions had a significantly shorter progression-free survival (PFS) (median 10.5 vs. 22.3 months, P = 0.0002) and shorter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Glycosylation and Glycoproteins Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17854306
DOI: 10.1111/j.1365-2141.2007.06750.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myelomaPMID 17854306Read ↗

Gain/Amplification of Chromosome Arm 1q21 in Multiple MyelomaSemantic proximity Read ↗

Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose ChemotherapySemantic proximity Read ↗

Chromosome 1q21 abnormalities in multiple myelomaSemantic proximity Read ↗

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalitiesSemantic proximity Read ↗

Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma PatientsSemantic proximity Read ↗

Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic TargetsSemantic proximity Read ↗

Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implicationsSemantic proximity Read ↗

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic valueSemantic proximity Read ↗

Prognostic significance of copy-number alterations in multiple myeloma.Semantic proximity Read ↗

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factorSemantic proximity Read ↗

Proteasome inhibitors and <scp>IM</scp>iDs can overcome some high‐risk cytogenetics in multiple myeloma but not gain 1q21Semantic proximity Read ↗

Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.